Overview Dividends

(CNTX) Context Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US21077P1084

Therapeutics, Oncology, Bispecific, Antibody, Solid Tumor

CNTX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 28.46%
EPS Trend (3Y Correlation): 78.3%

CNTX Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): -4.4%

Description: CNTX Context Therapeutics October 19, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) is a U.S. biopharma focused on solid-tumor therapies, centered on its lead bispecific antibody CTIM-76, which links anti-Claudin 6 (CLDN6) and anti-CD3 to direct T-cell killing of CLDN6-positive cancer cells. The firm’s development program is supported by a licensing and collaboration agreement with Integral Molecular, Inc., granting access to CLDN6-targeted antibody technology. Founded in 2015 and based in Philadelphia, the company trades under the “Pharmaceuticals” sub-industry in the GICS classification.

Key metrics that investors watch include a cash runway of roughly $45 million as of the latest 10-Q, a market-cap near $70 million, and a burn rate of about $12 million per quarter, indicating roughly 3–4 months of liquidity without additional financing. CLDN6 is overexpressed in several high-mortality cancers (e.g., ovarian, endometrial, and lung adenocarcinoma), a factor that aligns the program with the broader oncology trend of targeting tumor-specific antigens to improve efficacy and safety. The biotech sector’s recent surge in capital for bispecific and cell-engaging therapeutics-driven by strong investor appetite for next-generation immuno-oncology-provides a favorable financing environment for companies like Context.

For a deeper quantitative assessment of CNTX’s valuation and risk profile, you may find it useful to explore the analytics on ValueRay.

CNTX Stock Overview

Market Cap in USD	113m
Sub-Industry	Pharmaceuticals
IPO / Inception	2021-10-20

CNTX Stock Ratings

Growth Rating	-30.6%
Fundamental	30.6%
Dividend Rating	-
Return 12m vs S&P 500	-58.8%
Analyst Rating	4.40 of 5

CNTX Dividends

Currently no dividends paid

CNTX Growth Ratios

Growth Correlation 3m	87.8%
Growth Correlation 12m	-30.5%
Growth Correlation 5y	-42.1%
CAGR 5y	-2.35%
CAGR/Max DD 3y (Calmar Ratio)	-0.03
CAGR/Mean DD 3y (Pain Ratio)	-0.06
Sharpe Ratio 12m	-2.45
Alpha	-83.49
Beta	1.932
Volatility	91.33%
Current Volume	218k
Average Volume 20d	451.2k
Stop Loss	1 (-8.3%)
Signal	-0.76

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.25 (>2.0%) and ΔFCFTA -6.90pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.08 (>3.0%) and CFO -6.84m > Net Income -34.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 19.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (95.2m) change vs 12m ago 73.20% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 0.02%; Δ -0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -11.82 (EBITDA TTM -37.4m / Interest Expense TTM -3.16m) >= 6 (WARN >= 3)

Altman Z'' -25.14

(A) 0.94 = (Total Current Assets 86.7m - Total Current Liabilities 4.56m) / Total Assets 87.2m

(B) -1.24 = Retained Earnings (Balance) -108.2m / Total Assets 87.2m

warn (B) unusual magnitude: -1.24 — check mapping/units

(D) -23.46 = Book Value of Equity -108.1m / Total Liabilities 4.61m

Total Rating: -25.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.63

1. Piotroski 0.0pt = -5.0

2. FCF Yield -72.89% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.00 = 2.50

5. Debt/Ebitda 2.23 = -0.45

6. ROIC - WACC (= -46.60)% = -12.50

7. RoE -38.80% = -2.50

8. Rev. Trend -4.37% = -0.33

9. EPS Trend 78.27% = 3.91

What is the price of CNTX shares?

As of November 01, 2025, the stock is trading at USD 1.09 with a total of 217,995 shares traded.
Over the past week, the price has changed by -13.49%, over one month by +12.51%, over three months by +49.32% and over the past year by -50.00%.

Is Context Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Context Therapeutics (NASDAQ:CNTX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 30.63 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNTX is around 1.01 USD . This means that CNTX is currently overvalued and has a potential downside of -7.34%.

Is CNTX a buy, sell or hold?

Context Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy CNTX.

Strong Buy: 2
Buy: 3
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CNTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	5.2	374.3%
Analysts Target Price	5.2	374.3%
ValueRay Target Price	1.2	7.3%

CNTX Fundamental Data Overview October 18, 2025

Market Cap USD = 113.0m (113.0m USD * 1.0 USD.USD)
P/B = 1.0864
Beta = 1.932
Revenue TTM = 0.0 USD
EBIT TTM = -37.4m USD
EBITDA TTM = -37.4m USD
Long Term Debt = 167.3k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 115.0k USD (from shortTermDebt, last quarter)
Debt = 167.3k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -83.3m USD (from netDebt column, last quarter)
Enterprise Value = 29.7m USD (113.0m + Debt 167.3k - CCE 83.5m)
Interest Coverage Ratio = -11.82 (Ebit TTM -37.4m / Interest Expense TTM -3.16m)
FCF Yield = -72.89% (FCF TTM -21.6m / Enterprise Value 29.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 16.1k) / Revenue TTM)
Tobins Q-Ratio = 0.34 (Enterprise Value 29.7m / Total Assets 87.2m)
Interest Expense / Debt = 214.1% (Interest Expense 358.2k / Debt 167.3k)
Taxrate = 21.0% (US default 21%)
NOPAT = -29.5m (EBIT -37.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.04 (Total Current Assets 86.7m / Total Current Liabilities 4.56m)
Debt / Equity = 0.00 (Debt 167.3k / totalStockholderEquity, last quarter 82.5m)
Debt / EBITDA = 2.23 (negative EBITDA) (Net Debt -83.3m / EBITDA -37.4m)
Debt / FCF = 3.85 (negative FCF - burning cash) (Net Debt -83.3m / FCF TTM -21.6m)
Total Stockholder Equity = 88.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.25% (Net Income -34.2m / Total Assets 87.2m)
RoE = -38.80% (Net Income TTM -34.2m / Total Stockholder Equity 88.2m)
RoCE = -42.31% (EBIT -37.4m / Capital Employed (Equity 88.2m + L.T.Debt 167.3k))
RoIC = -33.48% (negative operating profit) (NOPAT -29.5m / Invested Capital 88.2m)
WACC = 13.11% (E(113.0m)/V(113.2m) * Re(13.13%) + (debt cost/tax rate unavailable))
Discount Rate = 13.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 144.2%
Fair Price DCF = unknown (Cash Flow -21.6m)
EPS Correlation: 78.27 | EPS CAGR: 28.46% | SUE: 0.76 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for CNTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle